nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—CYP3A4—Bexarotene—hematologic cancer	0.0356	0.0829	CbGbCtD
Lurasidone—CYP3A4—Lomustine—hematologic cancer	0.0331	0.0771	CbGbCtD
Lurasidone—CYP3A4—Busulfan—hematologic cancer	0.0331	0.0771	CbGbCtD
Lurasidone—CYP3A4—Thiotepa—hematologic cancer	0.0295	0.0687	CbGbCtD
Lurasidone—CYP3A4—Methoxsalen—hematologic cancer	0.0229	0.0534	CbGbCtD
Lurasidone—CYP3A4—Bortezomib—hematologic cancer	0.0218	0.0508	CbGbCtD
Lurasidone—CYP3A4—Daunorubicin—hematologic cancer	0.0209	0.0486	CbGbCtD
Lurasidone—CYP3A4—Cytarabine—hematologic cancer	0.0184	0.0429	CbGbCtD
Lurasidone—CYP3A4—Teniposide—hematologic cancer	0.0181	0.0422	CbGbCtD
Lurasidone—CYP3A4—Ifosfamide—hematologic cancer	0.0167	0.039	CbGbCtD
Lurasidone—CYP3A4—Imatinib—hematologic cancer	0.016	0.0372	CbGbCtD
Lurasidone—CYP3A4—Ruxolitinib—hematologic cancer	0.0151	0.035	CbGbCtD
Lurasidone—CYP3A4—Nilotinib—hematologic cancer	0.0145	0.0338	CbGbCtD
Lurasidone—CYP3A4—Vinorelbine—hematologic cancer	0.0144	0.0335	CbGbCtD
Lurasidone—CYP3A4—Triamcinolone—hematologic cancer	0.0132	0.0307	CbGbCtD
Lurasidone—CYP3A4—Dasatinib—hematologic cancer	0.0128	0.0299	CbGbCtD
Lurasidone—CYP3A4—Mitoxantrone—hematologic cancer	0.0127	0.0295	CbGbCtD
Lurasidone—CYP3A4—Betamethasone—hematologic cancer	0.0113	0.0263	CbGbCtD
Lurasidone—CYP3A4—Prednisolone—hematologic cancer	0.0112	0.026	CbGbCtD
Lurasidone—CYP3A4—Prednisone—hematologic cancer	0.0105	0.0245	CbGbCtD
Lurasidone—CYP3A4—Irinotecan—hematologic cancer	0.00999	0.0232	CbGbCtD
Lurasidone—CYP3A4—Vinblastine—hematologic cancer	0.00888	0.0207	CbGbCtD
Lurasidone—CYP3A4—Vincristine—hematologic cancer	0.00873	0.0203	CbGbCtD
Lurasidone—CYP3A4—Etoposide—hematologic cancer	0.008	0.0186	CbGbCtD
Lurasidone—CYP3A4—Dexamethasone—hematologic cancer	0.00658	0.0153	CbGbCtD
Lurasidone—CYP3A4—Doxorubicin—hematologic cancer	0.00546	0.0127	CbGbCtD
Lurasidone—Ziprasidone—H1F0—hematologic cancer	0.00531	1	CrCbGaD
Lurasidone—HTR1A—hematopoietic system—hematologic cancer	0.00062	0.0761	CbGeAlD
Lurasidone—HTR7—hematopoietic system—hematologic cancer	0.000593	0.0727	CbGeAlD
Lurasidone—HTR7—gonad—hematologic cancer	0.000451	0.0553	CbGeAlD
Lurasidone—ADRA2A—hematopoietic system—hematologic cancer	0.000435	0.0533	CbGeAlD
Lurasidone—HTR7—blood—hematologic cancer	0.000393	0.0482	CbGeAlD
Lurasidone—HTR2A—hematopoietic system—hematologic cancer	0.00037	0.0453	CbGeAlD
Lurasidone—ADRA2C—blood—hematologic cancer	0.000361	0.0443	CbGeAlD
Lurasidone—HTR7—lung—hematologic cancer	0.000344	0.0422	CbGeAlD
Lurasidone—CYP3A4—hematopoietic system—hematologic cancer	0.000342	0.042	CbGeAlD
Lurasidone—ADRA2A—gonad—hematologic cancer	0.00033	0.0406	CbGeAlD
Lurasidone—DRD2—lung—hematologic cancer	0.000325	0.0399	CbGeAlD
Lurasidone—HTR7—testis—hematologic cancer	0.000325	0.0399	CbGeAlD
Lurasidone—ADRA2C—lung—hematologic cancer	0.000316	0.0388	CbGeAlD
Lurasidone—DRD2—testis—hematologic cancer	0.000307	0.0377	CbGeAlD
Lurasidone—ADRA2C—testis—hematologic cancer	0.000299	0.0366	CbGeAlD
Lurasidone—ADRA2A—blood—hematologic cancer	0.000288	0.0353	CbGeAlD
Lurasidone—HTR2A—gonad—hematologic cancer	0.000281	0.0345	CbGeAlD
Lurasidone—ADRA2A—lung—hematologic cancer	0.000252	0.031	CbGeAlD
Lurasidone—HTR2A—blood—hematologic cancer	0.000245	0.03	CbGeAlD
Lurasidone—ADRA2A—testis—hematologic cancer	0.000238	0.0292	CbGeAlD
Lurasidone—CYP3A4—blood—hematologic cancer	0.000227	0.0278	CbGeAlD
Lurasidone—ADRA2C—lymph node—hematologic cancer	0.000216	0.0266	CbGeAlD
Lurasidone—HTR2A—lung—hematologic cancer	0.000215	0.0263	CbGeAlD
Lurasidone—HTR2A—testis—hematologic cancer	0.000203	0.0249	CbGeAlD
Lurasidone—ADRA2A—lymph node—hematologic cancer	0.000173	0.0212	CbGeAlD
Lurasidone—Vertigo—Prednisone—hematologic cancer	6.93e-05	0.000154	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—hematologic cancer	6.92e-05	0.000154	CcSEcCtD
Lurasidone—Syncope—Prednisone—hematologic cancer	6.92e-05	0.000154	CcSEcCtD
Lurasidone—Vomiting—Vincristine—hematologic cancer	6.89e-05	0.000153	CcSEcCtD
Lurasidone—Asthenia—Cisplatin—hematologic cancer	6.88e-05	0.000153	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—hematologic cancer	6.87e-05	0.000153	CcSEcCtD
Lurasidone—Fatigue—Triamcinolone—hematologic cancer	6.87e-05	0.000153	CcSEcCtD
Lurasidone—Urinary tract disorder—Epirubicin—hematologic cancer	6.84e-05	0.000152	CcSEcCtD
Lurasidone—Rash—Vincristine—hematologic cancer	6.84e-05	0.000152	CcSEcCtD
Lurasidone—Dermatitis—Vincristine—hematologic cancer	6.83e-05	0.000152	CcSEcCtD
Lurasidone—Connective tissue disorder—Epirubicin—hematologic cancer	6.81e-05	0.000152	CcSEcCtD
Lurasidone—Urethral disorder—Epirubicin—hematologic cancer	6.79e-05	0.000151	CcSEcCtD
Lurasidone—Loss of consciousness—Prednisone—hematologic cancer	6.78e-05	0.000151	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—hematologic cancer	6.75e-05	0.00015	CcSEcCtD
Lurasidone—Hypotension—Dexamethasone—hematologic cancer	6.75e-05	0.00015	CcSEcCtD
Lurasidone—Hypotension—Betamethasone—hematologic cancer	6.75e-05	0.00015	CcSEcCtD
Lurasidone—Nausea—Carmustine—hematologic cancer	6.75e-05	0.00015	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—hematologic cancer	6.72e-05	0.00015	CcSEcCtD
Lurasidone—Vomiting—Irinotecan—hematologic cancer	6.71e-05	0.000149	CcSEcCtD
Lurasidone—Vomiting—Mitoxantrone—hematologic cancer	6.71e-05	0.000149	CcSEcCtD
Lurasidone—Nausea—Alitretinoin—hematologic cancer	6.68e-05	0.000149	CcSEcCtD
Lurasidone—Convulsion—Prednisone—hematologic cancer	6.68e-05	0.000149	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—hematologic cancer	6.66e-05	0.000148	CcSEcCtD
Lurasidone—Hypertension—Prednisone—hematologic cancer	6.66e-05	0.000148	CcSEcCtD
Lurasidone—Rash—Irinotecan—hematologic cancer	6.66e-05	0.000148	CcSEcCtD
Lurasidone—Rash—Mitoxantrone—hematologic cancer	6.66e-05	0.000148	CcSEcCtD
Lurasidone—Dermatitis—Mitoxantrone—hematologic cancer	6.65e-05	0.000148	CcSEcCtD
Lurasidone—Dermatitis—Irinotecan—hematologic cancer	6.65e-05	0.000148	CcSEcCtD
Lurasidone—Nausea—Ifosfamide—hematologic cancer	6.6e-05	0.000147	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Betamethasone—hematologic cancer	6.58e-05	0.000147	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	6.58e-05	0.000147	CcSEcCtD
Lurasidone—Myalgia—Prednisone—hematologic cancer	6.57e-05	0.000146	CcSEcCtD
Lurasidone—Diarrhoea—Cisplatin—hematologic cancer	6.56e-05	0.000146	CcSEcCtD
Lurasidone—Anxiety—Prednisone—hematologic cancer	6.54e-05	0.000146	CcSEcCtD
Lurasidone—Vomiting—Gemcitabine—hematologic cancer	6.54e-05	0.000146	CcSEcCtD
Lurasidone—Insomnia—Dexamethasone—hematologic cancer	6.54e-05	0.000146	CcSEcCtD
Lurasidone—Insomnia—Betamethasone—hematologic cancer	6.54e-05	0.000146	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—hematologic cancer	6.53e-05	0.000145	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.52e-05	0.000145	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—hematologic cancer	6.49e-05	0.000144	CcSEcCtD
Lurasidone—Rash—Gemcitabine—hematologic cancer	6.48e-05	0.000144	CcSEcCtD
Lurasidone—Dermatitis—Gemcitabine—hematologic cancer	6.48e-05	0.000144	CcSEcCtD
Lurasidone—Eye disorder—Epirubicin—hematologic cancer	6.48e-05	0.000144	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—hematologic cancer	6.45e-05	0.000144	CcSEcCtD
Lurasidone—Nausea—Vincristine—hematologic cancer	6.44e-05	0.000143	CcSEcCtD
Lurasidone—Cardiac disorder—Epirubicin—hematologic cancer	6.43e-05	0.000143	CcSEcCtD
Lurasidone—Dyspepsia—Betamethasone—hematologic cancer	6.36e-05	0.000142	CcSEcCtD
Lurasidone—Dyspepsia—Dexamethasone—hematologic cancer	6.36e-05	0.000142	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—hematologic cancer	6.33e-05	0.000141	CcSEcCtD
Lurasidone—Asthenia—Etoposide—hematologic cancer	6.3e-05	0.00014	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—hematologic cancer	6.3e-05	0.00014	CcSEcCtD
Lurasidone—Angiopathy—Epirubicin—hematologic cancer	6.29e-05	0.00014	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—hematologic cancer	6.28e-05	0.00014	CcSEcCtD
Lurasidone—Decreased appetite—Betamethasone—hematologic cancer	6.28e-05	0.00014	CcSEcCtD
Lurasidone—Decreased appetite—Dexamethasone—hematologic cancer	6.28e-05	0.00014	CcSEcCtD
Lurasidone—Nausea—Mitoxantrone—hematologic cancer	6.27e-05	0.00014	CcSEcCtD
Lurasidone—Nausea—Irinotecan—hematologic cancer	6.27e-05	0.00014	CcSEcCtD
Lurasidone—Infection—Prednisone—hematologic cancer	6.25e-05	0.000139	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Dexamethasone—hematologic cancer	6.24e-05	0.000139	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Betamethasone—hematologic cancer	6.24e-05	0.000139	CcSEcCtD
Lurasidone—Back pain—Methotrexate—hematologic cancer	6.23e-05	0.000139	CcSEcCtD
Lurasidone—Fatigue—Dexamethasone—hematologic cancer	6.23e-05	0.000139	CcSEcCtD
Lurasidone—Fatigue—Betamethasone—hematologic cancer	6.23e-05	0.000139	CcSEcCtD
Lurasidone—Pruritus—Etoposide—hematologic cancer	6.21e-05	0.000138	CcSEcCtD
Lurasidone—Shock—Prednisone—hematologic cancer	6.19e-05	0.000138	CcSEcCtD
Lurasidone—Arrhythmia—Epirubicin—hematologic cancer	6.19e-05	0.000138	CcSEcCtD
Lurasidone—Nervous system disorder—Prednisone—hematologic cancer	6.17e-05	0.000137	CcSEcCtD
Lurasidone—Tachycardia—Prednisone—hematologic cancer	6.14e-05	0.000137	CcSEcCtD
Lurasidone—Skin disorder—Prednisone—hematologic cancer	6.11e-05	0.000136	CcSEcCtD
Lurasidone—Nausea—Gemcitabine—hematologic cancer	6.11e-05	0.000136	CcSEcCtD
Lurasidone—Vomiting—Cisplatin—hematologic cancer	6.09e-05	0.000136	CcSEcCtD
Lurasidone—Hyperhidrosis—Prednisone—hematologic cancer	6.08e-05	0.000136	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—hematologic cancer	6.07e-05	0.000135	CcSEcCtD
Lurasidone—Mental disorder—Epirubicin—hematologic cancer	6.07e-05	0.000135	CcSEcCtD
Lurasidone—Rash—Cisplatin—hematologic cancer	6.04e-05	0.000135	CcSEcCtD
Lurasidone—Dermatitis—Cisplatin—hematologic cancer	6.04e-05	0.000134	CcSEcCtD
Lurasidone—Malnutrition—Epirubicin—hematologic cancer	6.03e-05	0.000134	CcSEcCtD
Lurasidone—Diarrhoea—Etoposide—hematologic cancer	6.01e-05	0.000134	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—hematologic cancer	5.99e-05	0.000133	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—hematologic cancer	5.96e-05	0.000133	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—hematologic cancer	5.95e-05	0.000133	CcSEcCtD
Lurasidone—Flatulence—Epirubicin—hematologic cancer	5.94e-05	0.000132	CcSEcCtD
Lurasidone—Gastrointestinal pain—Betamethasone—hematologic cancer	5.91e-05	0.000132	CcSEcCtD
Lurasidone—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.91e-05	0.000132	CcSEcCtD
Lurasidone—Back pain—Epirubicin—hematologic cancer	5.83e-05	0.00013	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—hematologic cancer	5.82e-05	0.00013	CcSEcCtD
Lurasidone—Malaise—Methotrexate—hematologic cancer	5.81e-05	0.000129	CcSEcCtD
Lurasidone—Dizziness—Etoposide—hematologic cancer	5.81e-05	0.000129	CcSEcCtD
Lurasidone—Muscle spasms—Epirubicin—hematologic cancer	5.8e-05	0.000129	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—hematologic cancer	5.79e-05	0.000129	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—hematologic cancer	5.77e-05	0.000128	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.73e-05	0.000128	CcSEcCtD
Lurasidone—Dizziness—Prednisolone—hematologic cancer	5.73e-05	0.000128	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—hematologic cancer	5.73e-05	0.000128	CcSEcCtD
Lurasidone—Asthenia—Triamcinolone—hematologic cancer	5.71e-05	0.000127	CcSEcCtD
Lurasidone—Abdominal pain—Betamethasone—hematologic cancer	5.71e-05	0.000127	CcSEcCtD
Lurasidone—Abdominal pain—Dexamethasone—hematologic cancer	5.71e-05	0.000127	CcSEcCtD
Lurasidone—Nausea—Cisplatin—hematologic cancer	5.69e-05	0.000127	CcSEcCtD
Lurasidone—Insomnia—Prednisone—hematologic cancer	5.69e-05	0.000127	CcSEcCtD
Lurasidone—Vision blurred—Epirubicin—hematologic cancer	5.68e-05	0.000127	CcSEcCtD
Lurasidone—Pruritus—Triamcinolone—hematologic cancer	5.64e-05	0.000125	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—hematologic cancer	5.62e-05	0.000125	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—hematologic cancer	5.58e-05	0.000124	CcSEcCtD
Lurasidone—Vomiting—Etoposide—hematologic cancer	5.58e-05	0.000124	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—hematologic cancer	5.58e-05	0.000124	CcSEcCtD
Lurasidone—Anaemia—Epirubicin—hematologic cancer	5.57e-05	0.000124	CcSEcCtD
Lurasidone—Agitation—Epirubicin—hematologic cancer	5.54e-05	0.000123	CcSEcCtD
Lurasidone—Dyspepsia—Prednisone—hematologic cancer	5.54e-05	0.000123	CcSEcCtD
Lurasidone—Rash—Etoposide—hematologic cancer	5.54e-05	0.000123	CcSEcCtD
Lurasidone—Dermatitis—Etoposide—hematologic cancer	5.53e-05	0.000123	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—hematologic cancer	5.5e-05	0.000122	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—hematologic cancer	5.49e-05	0.000122	CcSEcCtD
Lurasidone—Decreased appetite—Prednisone—hematologic cancer	5.47e-05	0.000122	CcSEcCtD
Lurasidone—Rash—Prednisolone—hematologic cancer	5.46e-05	0.000122	CcSEcCtD
Lurasidone—Dermatitis—Prednisolone—hematologic cancer	5.46e-05	0.000122	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.45e-05	0.000121	CcSEcCtD
Lurasidone—Malaise—Epirubicin—hematologic cancer	5.44e-05	0.000121	CcSEcCtD
Lurasidone—Fatigue—Prednisone—hematologic cancer	5.43e-05	0.000121	CcSEcCtD
Lurasidone—Vertigo—Epirubicin—hematologic cancer	5.42e-05	0.000121	CcSEcCtD
Lurasidone—Syncope—Epirubicin—hematologic cancer	5.41e-05	0.00012	CcSEcCtD
Lurasidone—Leukopenia—Epirubicin—hematologic cancer	5.4e-05	0.00012	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—hematologic cancer	5.4e-05	0.00012	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—hematologic cancer	5.37e-05	0.000119	CcSEcCtD
Lurasidone—Loss of consciousness—Epirubicin—hematologic cancer	5.3e-05	0.000118	CcSEcCtD
Lurasidone—Dizziness—Triamcinolone—hematologic cancer	5.27e-05	0.000117	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—hematologic cancer	5.26e-05	0.000117	CcSEcCtD
Lurasidone—Convulsion—Epirubicin—hematologic cancer	5.23e-05	0.000116	CcSEcCtD
Lurasidone—Infection—Methotrexate—hematologic cancer	5.23e-05	0.000116	CcSEcCtD
Lurasidone—Nausea—Etoposide—hematologic cancer	5.22e-05	0.000116	CcSEcCtD
Lurasidone—Hypertension—Epirubicin—hematologic cancer	5.21e-05	0.000116	CcSEcCtD
Lurasidone—Asthenia—Dexamethasone—hematologic cancer	5.19e-05	0.000115	CcSEcCtD
Lurasidone—Asthenia—Betamethasone—hematologic cancer	5.19e-05	0.000115	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—hematologic cancer	5.16e-05	0.000115	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—hematologic cancer	5.16e-05	0.000115	CcSEcCtD
Lurasidone—Gastrointestinal pain—Prednisone—hematologic cancer	5.15e-05	0.000115	CcSEcCtD
Lurasidone—Nausea—Prednisolone—hematologic cancer	5.14e-05	0.000115	CcSEcCtD
Lurasidone—Myalgia—Epirubicin—hematologic cancer	5.13e-05	0.000114	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—hematologic cancer	5.13e-05	0.000114	CcSEcCtD
Lurasidone—Anxiety—Epirubicin—hematologic cancer	5.12e-05	0.000114	CcSEcCtD
Lurasidone—Pruritus—Dexamethasone—hematologic cancer	5.11e-05	0.000114	CcSEcCtD
Lurasidone—Pruritus—Betamethasone—hematologic cancer	5.11e-05	0.000114	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—hematologic cancer	5.11e-05	0.000114	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.1e-05	0.000114	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—hematologic cancer	5.09e-05	0.000113	CcSEcCtD
Lurasidone—Vomiting—Triamcinolone—hematologic cancer	5.06e-05	0.000113	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—hematologic cancer	5.03e-05	0.000112	CcSEcCtD
Lurasidone—Rash—Triamcinolone—hematologic cancer	5.02e-05	0.000112	CcSEcCtD
Lurasidone—Dry mouth—Epirubicin—hematologic cancer	5.02e-05	0.000112	CcSEcCtD
Lurasidone—Dermatitis—Triamcinolone—hematologic cancer	5.02e-05	0.000112	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—hematologic cancer	5.01e-05	0.000112	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—hematologic cancer	5e-05	0.000111	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—hematologic cancer	5e-05	0.000111	CcSEcCtD
Lurasidone—Abdominal pain—Prednisone—hematologic cancer	4.98e-05	0.000111	CcSEcCtD
Lurasidone—Diarrhoea—Betamethasone—hematologic cancer	4.94e-05	0.00011	CcSEcCtD
Lurasidone—Diarrhoea—Dexamethasone—hematologic cancer	4.94e-05	0.00011	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—hematologic cancer	4.92e-05	0.000109	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—hematologic cancer	4.91e-05	0.000109	CcSEcCtD
Lurasidone—Infection—Epirubicin—hematologic cancer	4.89e-05	0.000109	CcSEcCtD
Lurasidone—Shock—Epirubicin—hematologic cancer	4.84e-05	0.000108	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—hematologic cancer	4.84e-05	0.000108	CcSEcCtD
Lurasidone—Nervous system disorder—Epirubicin—hematologic cancer	4.83e-05	0.000108	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—hematologic cancer	4.82e-05	0.000107	CcSEcCtD
Lurasidone—Tachycardia—Epirubicin—hematologic cancer	4.8e-05	0.000107	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.79e-05	0.000107	CcSEcCtD
Lurasidone—Skin disorder—Epirubicin—hematologic cancer	4.78e-05	0.000106	CcSEcCtD
Lurasidone—Dizziness—Betamethasone—hematologic cancer	4.78e-05	0.000106	CcSEcCtD
Lurasidone—Dizziness—Dexamethasone—hematologic cancer	4.78e-05	0.000106	CcSEcCtD
Lurasidone—Hyperhidrosis—Epirubicin—hematologic cancer	4.76e-05	0.000106	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—hematologic cancer	4.76e-05	0.000106	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—hematologic cancer	4.75e-05	0.000106	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—hematologic cancer	4.73e-05	0.000105	CcSEcCtD
Lurasidone—Nausea—Triamcinolone—hematologic cancer	4.73e-05	0.000105	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.72e-05	0.000105	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—hematologic cancer	4.69e-05	0.000104	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—hematologic cancer	4.68e-05	0.000104	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—hematologic cancer	4.65e-05	0.000103	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—hematologic cancer	4.63e-05	0.000103	CcSEcCtD
Lurasidone—Hypotension—Epirubicin—hematologic cancer	4.6e-05	0.000102	CcSEcCtD
Lurasidone—Vomiting—Betamethasone—hematologic cancer	4.6e-05	0.000102	CcSEcCtD
Lurasidone—Vomiting—Dexamethasone—hematologic cancer	4.6e-05	0.000102	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—hematologic cancer	4.57e-05	0.000102	CcSEcCtD
Lurasidone—Rash—Betamethasone—hematologic cancer	4.56e-05	0.000101	CcSEcCtD
Lurasidone—Rash—Dexamethasone—hematologic cancer	4.56e-05	0.000101	CcSEcCtD
Lurasidone—Dermatitis—Dexamethasone—hematologic cancer	4.55e-05	0.000101	CcSEcCtD
Lurasidone—Dermatitis—Betamethasone—hematologic cancer	4.55e-05	0.000101	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.54e-05	0.000101	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—hematologic cancer	4.53e-05	0.000101	CcSEcCtD
Lurasidone—Infection—Doxorubicin—hematologic cancer	4.52e-05	0.000101	CcSEcCtD
Lurasidone—Asthenia—Prednisone—hematologic cancer	4.52e-05	0.000101	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.48e-05	9.99e-05	CcSEcCtD
Lurasidone—Shock—Doxorubicin—hematologic cancer	4.48e-05	9.98e-05	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—hematologic cancer	4.47e-05	9.95e-05	CcSEcCtD
Lurasidone—Pruritus—Prednisone—hematologic cancer	4.45e-05	9.92e-05	CcSEcCtD
Lurasidone—Insomnia—Epirubicin—hematologic cancer	4.45e-05	9.92e-05	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—hematologic cancer	4.45e-05	9.9e-05	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—hematologic cancer	4.42e-05	9.85e-05	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—hematologic cancer	4.4e-05	9.81e-05	CcSEcCtD
Lurasidone—Dyspnoea—Epirubicin—hematologic cancer	4.39e-05	9.77e-05	CcSEcCtD
Lurasidone—Somnolence—Epirubicin—hematologic cancer	4.38e-05	9.75e-05	CcSEcCtD
Lurasidone—Dyspepsia—Epirubicin—hematologic cancer	4.33e-05	9.65e-05	CcSEcCtD
Lurasidone—Diarrhoea—Prednisone—hematologic cancer	4.31e-05	9.59e-05	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—hematologic cancer	4.3e-05	9.58e-05	CcSEcCtD
Lurasidone—Nausea—Betamethasone—hematologic cancer	4.29e-05	9.56e-05	CcSEcCtD
Lurasidone—Nausea—Dexamethasone—hematologic cancer	4.29e-05	9.56e-05	CcSEcCtD
Lurasidone—Decreased appetite—Epirubicin—hematologic cancer	4.28e-05	9.53e-05	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—hematologic cancer	4.26e-05	9.48e-05	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.25e-05	9.46e-05	CcSEcCtD
Lurasidone—Fatigue—Epirubicin—hematologic cancer	4.24e-05	9.45e-05	CcSEcCtD
Lurasidone—Dizziness—Prednisone—hematologic cancer	4.16e-05	9.27e-05	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—hematologic cancer	4.16e-05	9.26e-05	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.15e-05	9.24e-05	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—hematologic cancer	4.12e-05	9.17e-05	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—hematologic cancer	4.06e-05	9.04e-05	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—hematologic cancer	4.05e-05	9.02e-05	CcSEcCtD
Lurasidone—Gastrointestinal pain—Epirubicin—hematologic cancer	4.03e-05	8.96e-05	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—hematologic cancer	4.01e-05	8.93e-05	CcSEcCtD
Lurasidone—Vomiting—Prednisone—hematologic cancer	4e-05	8.91e-05	CcSEcCtD
Lurasidone—Rash—Prednisone—hematologic cancer	3.97e-05	8.84e-05	CcSEcCtD
Lurasidone—Dermatitis—Prednisone—hematologic cancer	3.96e-05	8.83e-05	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—hematologic cancer	3.96e-05	8.82e-05	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.93e-05	8.76e-05	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—hematologic cancer	3.93e-05	8.75e-05	CcSEcCtD
Lurasidone—Abdominal pain—Epirubicin—hematologic cancer	3.89e-05	8.67e-05	CcSEcCtD
Lurasidone—Asthenia—Methotrexate—hematologic cancer	3.77e-05	8.4e-05	CcSEcCtD
Lurasidone—Nausea—Prednisone—hematologic cancer	3.74e-05	8.33e-05	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.72e-05	8.29e-05	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—hematologic cancer	3.72e-05	8.29e-05	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—hematologic cancer	3.6e-05	8.02e-05	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—hematologic cancer	3.6e-05	8.01e-05	CcSEcCtD
Lurasidone—Asthenia—Epirubicin—hematologic cancer	3.53e-05	7.87e-05	CcSEcCtD
Lurasidone—Pruritus—Epirubicin—hematologic cancer	3.48e-05	7.76e-05	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—hematologic cancer	3.48e-05	7.75e-05	CcSEcCtD
Lurasidone—Diarrhoea—Epirubicin—hematologic cancer	3.37e-05	7.5e-05	CcSEcCtD
Lurasidone—Vomiting—Methotrexate—hematologic cancer	3.34e-05	7.45e-05	CcSEcCtD
Lurasidone—Rash—Methotrexate—hematologic cancer	3.32e-05	7.39e-05	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—hematologic cancer	3.31e-05	7.38e-05	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—hematologic cancer	3.27e-05	7.28e-05	CcSEcCtD
Lurasidone—Dizziness—Epirubicin—hematologic cancer	3.26e-05	7.25e-05	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—hematologic cancer	3.22e-05	7.18e-05	CcSEcCtD
Lurasidone—Vomiting—Epirubicin—hematologic cancer	3.13e-05	6.97e-05	CcSEcCtD
Lurasidone—Nausea—Methotrexate—hematologic cancer	3.12e-05	6.96e-05	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—hematologic cancer	3.12e-05	6.94e-05	CcSEcCtD
Lurasidone—Rash—Epirubicin—hematologic cancer	3.1e-05	6.91e-05	CcSEcCtD
Lurasidone—Dermatitis—Epirubicin—hematologic cancer	3.1e-05	6.91e-05	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—hematologic cancer	3.01e-05	6.71e-05	CcSEcCtD
Lurasidone—Nausea—Epirubicin—hematologic cancer	2.92e-05	6.51e-05	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—hematologic cancer	2.9e-05	6.45e-05	CcSEcCtD
Lurasidone—Rash—Doxorubicin—hematologic cancer	2.87e-05	6.4e-05	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—hematologic cancer	2.87e-05	6.39e-05	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—hematologic cancer	2.71e-05	6.02e-05	CcSEcCtD
Lurasidone—DRD2—Signaling by GPCR—MAPK3—hematologic cancer	7.72e-06	7.16e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CREB1—hematologic cancer	7.68e-06	7.11e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—KRAS—hematologic cancer	7.65e-06	7.09e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	7.64e-06	7.08e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3R1—hematologic cancer	7.62e-06	7.07e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SRC—hematologic cancer	7.61e-06	7.05e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SDC1—hematologic cancer	7.6e-06	7.04e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—MAPK3—hematologic cancer	7.6e-06	7.04e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CD—hematologic cancer	7.59e-06	7.03e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—BRAF—hematologic cancer	7.58e-06	7.03e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CREB1—hematologic cancer	7.55e-06	7e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FN1—hematologic cancer	7.54e-06	6.99e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCL2—hematologic cancer	7.51e-06	6.96e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALB—hematologic cancer	7.49e-06	6.94e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6R—hematologic cancer	7.49e-06	6.94e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—FGF2—hematologic cancer	7.48e-06	6.93e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CREBBP—hematologic cancer	7.48e-06	6.93e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—BRAF—hematologic cancer	7.46e-06	6.91e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—BAD—hematologic cancer	7.45e-06	6.91e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	7.45e-06	6.91e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—hematologic cancer	7.41e-06	6.87e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—JAK2—hematologic cancer	7.41e-06	6.87e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCL2—hematologic cancer	7.39e-06	6.85e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	7.38e-06	6.84e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3R1—hematologic cancer	7.38e-06	6.84e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6R—hematologic cancer	7.37e-06	6.83e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CREBBP—hematologic cancer	7.36e-06	6.82e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—STAT3—hematologic cancer	7.34e-06	6.8e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NRAS—hematologic cancer	7.32e-06	6.79e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PIK3CA—hematologic cancer	7.26e-06	6.73e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MDM2—hematologic cancer	7.23e-06	6.7e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CD80—hematologic cancer	7.23e-06	6.7e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	7.22e-06	6.69e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KIT—hematologic cancer	7.22e-06	6.69e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	7.22e-06	6.69e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—JAK2—hematologic cancer	7.17e-06	6.65e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3R1—hematologic cancer	7.17e-06	6.64e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAP2K1—hematologic cancer	7.14e-06	6.61e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	7.09e-06	6.57e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CD—hematologic cancer	7.09e-06	6.57e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MTOR—hematologic cancer	7.04e-06	6.52e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CB—hematologic cancer	7.04e-06	6.52e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTEN—hematologic cancer	7.04e-06	6.52e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PIK3CA—hematologic cancer	7.03e-06	6.51e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PIK3CA—hematologic cancer	7.02e-06	6.51e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAP2K1—hematologic cancer	7.02e-06	6.51e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK3—hematologic cancer	7.01e-06	6.5e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MDM2—hematologic cancer	7e-06	6.49e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CD—hematologic cancer	6.97e-06	6.47e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KRAS—hematologic cancer	6.94e-06	6.43e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	6.91e-06	6.41e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PIK3CA—hematologic cancer	6.91e-06	6.4e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	6.87e-06	6.37e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KRAS—hematologic cancer	6.83e-06	6.33e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—hematologic cancer	6.82e-06	6.32e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MTOR—hematologic cancer	6.81e-06	6.31e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CB—hematologic cancer	6.81e-06	6.31e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TGFB1—hematologic cancer	6.8e-06	6.31e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—FGF2—hematologic cancer	6.79e-06	6.29e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	6.78e-06	6.29e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	6.72e-06	6.23e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—HRAS—hematologic cancer	6.72e-06	6.23e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—EP300—hematologic cancer	6.71e-06	6.22e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	6.7e-06	6.21e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3R1—hematologic cancer	6.69e-06	6.2e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	6.69e-06	6.2e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—FGF2—hematologic cancer	6.68e-06	6.19e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CB—hematologic cancer	6.61e-06	6.13e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1B—hematologic cancer	6.6e-06	6.12e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	6.59e-06	6.11e-05	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—hematologic cancer	6.53e-06	6.06e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—JAK2—hematologic cancer	6.51e-06	6.03e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—HRAS—hematologic cancer	6.5e-06	6.03e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CASP3—hematologic cancer	6.47e-06	6e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL2—hematologic cancer	6.46e-06	5.99e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NQO1—hematologic cancer	6.46e-06	5.99e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CD44—hematologic cancer	6.46e-06	5.99e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—hematologic cancer	6.43e-06	5.96e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—JAK2—hematologic cancer	6.4e-06	5.93e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1B—hematologic cancer	6.39e-06	5.92e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	6.39e-06	5.92e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PIK3CA—hematologic cancer	6.38e-06	5.91e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MDM2—hematologic cancer	6.35e-06	5.89e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	6.35e-06	5.88e-05	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—hematologic cancer	6.32e-06	5.86e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KRAS—hematologic cancer	6.3e-06	5.84e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCND1—hematologic cancer	6.3e-06	5.84e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—JUN—hematologic cancer	6.29e-06	5.83e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	6.29e-06	5.83e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	6.27e-06	5.82e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CASP3—hematologic cancer	6.26e-06	5.81e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL2—hematologic cancer	6.25e-06	5.8e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MDM2—hematologic cancer	6.25e-06	5.79e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—hematologic cancer	6.22e-06	5.77e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	6.21e-06	5.76e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MTOR—hematologic cancer	6.18e-06	5.73e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CB—hematologic cancer	6.18e-06	5.73e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYCS—hematologic cancer	6.11e-06	5.67e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCND1—hematologic cancer	6.1e-06	5.65e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	6.09e-06	5.65e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—JUN—hematologic cancer	6.08e-06	5.64e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTEN—hematologic cancer	6.08e-06	5.64e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MTOR—hematologic cancer	6.08e-06	5.64e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	6.08e-06	5.64e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	6.08e-06	5.63e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	6.08e-06	5.63e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	5.99e-06	5.55e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	5.95e-06	5.51e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	5.93e-06	5.5e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—HRAS—hematologic cancer	5.9e-06	5.47e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	5.9e-06	5.47e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	5.88e-06	5.45e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	5.82e-06	5.4e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	5.8e-06	5.38e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EP300—hematologic cancer	5.8e-06	5.38e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	5.8e-06	5.37e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CA—hematologic cancer	5.79e-06	5.37e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	5.76e-06	5.34e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	5.74e-06	5.32e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	5.74e-06	5.32e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTEN—hematologic cancer	5.72e-06	5.3e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	5.71e-06	5.29e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	5.71e-06	5.29e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	5.68e-06	5.27e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CASP3—hematologic cancer	5.68e-06	5.27e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL2—hematologic cancer	5.67e-06	5.26e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—hematologic cancer	5.65e-06	5.23e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	5.64e-06	5.23e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SRC—hematologic cancer	5.64e-06	5.23e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EP300—hematologic cancer	5.61e-06	5.2e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—hematologic cancer	5.6e-06	5.19e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CASP3—hematologic cancer	5.59e-06	5.18e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL2—hematologic cancer	5.58e-06	5.18e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—hematologic cancer	5.56e-06	5.15e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCND1—hematologic cancer	5.53e-06	5.13e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	5.53e-06	5.13e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	5.53e-06	5.13e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—JUN—hematologic cancer	5.52e-06	5.12e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	5.49e-06	5.09e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SRC—hematologic cancer	5.46e-06	5.06e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—EP300—hematologic cancer	5.45e-06	5.05e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCND1—hematologic cancer	5.44e-06	5.05e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—hematologic cancer	5.44e-06	5.04e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—JUN—hematologic cancer	5.43e-06	5.03e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NRAS—hematologic cancer	5.43e-06	5.03e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTP1—hematologic cancer	5.39e-06	5e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HRAS—hematologic cancer	5.36e-06	4.96e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	5.35e-06	4.96e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTEN—hematologic cancer	5.34e-06	4.95e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	5.31e-06	4.93e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	5.28e-06	4.89e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	5.27e-06	4.88e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	5.26e-06	4.88e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTEN—hematologic cancer	5.25e-06	4.87e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	5.25e-06	4.87e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK8—hematologic cancer	5.22e-06	4.84e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—hematologic cancer	5.21e-06	4.83e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	5.2e-06	4.82e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	5.19e-06	4.81e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	5.14e-06	4.76e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	5.13e-06	4.76e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—hematologic cancer	5.13e-06	4.75e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	5.13e-06	4.75e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ABCB1—hematologic cancer	5.1e-06	4.73e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EP300—hematologic cancer	5.09e-06	4.72e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	5.09e-06	4.72e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL2—hematologic cancer	5.08e-06	4.71e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	5.05e-06	4.69e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—hematologic cancer	5.05e-06	4.68e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	5.04e-06	4.67e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	5.03e-06	4.66e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EP300—hematologic cancer	5.01e-06	4.64e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CA—hematologic cancer	4.96e-06	4.6e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NCOR1—hematologic cancer	4.95e-06	4.59e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTM1—hematologic cancer	4.95e-06	4.59e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	4.95e-06	4.59e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SRC—hematologic cancer	4.95e-06	4.59e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—JUN—hematologic cancer	4.94e-06	4.58e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—hematologic cancer	4.89e-06	4.53e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	4.88e-06	4.52e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SRC—hematologic cancer	4.87e-06	4.52e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—hematologic cancer	4.82e-06	4.47e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	4.79e-06	4.44e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	4.78e-06	4.43e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—hematologic cancer	4.77e-06	4.43e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NRAS—hematologic cancer	4.76e-06	4.42e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	4.75e-06	4.4e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—hematologic cancer	4.73e-06	4.38e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—hematologic cancer	4.7e-06	4.36e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NRAS—hematologic cancer	4.69e-06	4.34e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	4.68e-06	4.33e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KRAS—hematologic cancer	4.67e-06	4.33e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	4.66e-06	4.32e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK3—hematologic cancer	4.56e-06	4.23e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EP300—hematologic cancer	4.56e-06	4.23e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	4.52e-06	4.19e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	4.49e-06	4.16e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—hematologic cancer	4.44e-06	4.11e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SRC—hematologic cancer	4.43e-06	4.11e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TGFB1—hematologic cancer	4.43e-06	4.1e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—MTHFR—hematologic cancer	4.38e-06	4.06e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—hematologic cancer	4.37e-06	4.05e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	4.36e-06	4.04e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	4.32e-06	4e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	4.29e-06	3.98e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	4.27e-06	3.96e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	4.26e-06	3.95e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	4.15e-06	3.85e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—hematologic cancer	4.15e-06	3.85e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KRAS—hematologic cancer	4.1e-06	3.8e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	4.08e-06	3.79e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—hematologic cancer	4.06e-06	3.76e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KRAS—hematologic cancer	4.03e-06	3.74e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CA—hematologic cancer	4.03e-06	3.74e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—hematologic cancer	4.02e-06	3.72e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—hematologic cancer	3.97e-06	3.68e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HRAS—hematologic cancer	3.97e-06	3.68e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	3.96e-06	3.67e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	3.84e-06	3.56e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—hematologic cancer	3.8e-06	3.52e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	3.77e-06	3.49e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	3.71e-06	3.44e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CG—hematologic cancer	3.68e-06	3.41e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—hematologic cancer	3.68e-06	3.41e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	3.67e-06	3.4e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—hematologic cancer	3.64e-06	3.38e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—hematologic cancer	3.59e-06	3.32e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—hematologic cancer	3.5e-06	3.25e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HRAS—hematologic cancer	3.48e-06	3.23e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HRAS—hematologic cancer	3.43e-06	3.18e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CREBBP—hematologic cancer	3.41e-06	3.16e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	3.39e-06	3.14e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	3.37e-06	3.13e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—hematologic cancer	3.34e-06	3.09e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—hematologic cancer	3.29e-06	3.05e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—hematologic cancer	3.28e-06	3.04e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—hematologic cancer	3.26e-06	3.02e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CD—hematologic cancer	3.23e-06	3e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALB—hematologic cancer	3.19e-06	2.96e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	3.12e-06	2.89e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—hematologic cancer	3.08e-06	2.85e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3R1—hematologic cancer	3.05e-06	2.83e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—hematologic cancer	3.03e-06	2.81e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—hematologic cancer	2.99e-06	2.77e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.82e-06	2.61e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	2.75e-06	2.55e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTEN—hematologic cancer	2.44e-06	2.26e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—EP300—hematologic cancer	2.32e-06	2.15e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.72e-06	1.59e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—hematologic cancer	1.4e-06	1.3e-05	CbGpPWpGaD
